Lifting & Tightening
Thermage and Oligio: What Can Be Compared?
Thermage and Oligio name separate radiofrequency (RF) devices. The sources describe a general RF principle and a prospective cohort using one Oligio device, with no Thermage comparison group. The reported 6.78 MHz frequency belongs to that studied device. One treatment followed through day 180 cannot tell us how long a result lasts, when another treatment should occur, whether the devices are equivalent, or which performs better.
- The cited study did not directly compare Thermage and Oligio performance.
- The 6.78 MHz figure applies to the studied Oligio device, not to another model.
- A single-group design cannot establish superiority or equivalence between device names.
Any comparison depends on the exact model, energy delivery, electrode configuration, frequency, cooling method, and supporting study design. The cited cohort observed one device. It offers no head-to-head result or outcome ranking. The names identify devices; they are not a recommendation.
General RF principles and device configuration
For this comparison, the hospital’s explanation that RF can provide thermal stimulation in deeper dermal tissue is general background; it does not compare the devices or establish that their configurations or performance match.
The 6.78 MHz value belongs to the studied device
In Dermatology and Therapy, researchers used a monopolar RF Oligio device operating at 6.78 MHz. The paper classifies RF devices by electrode number and how they transmit energy to subcutaneous tissue. Frequency and monopolar design describe only part of a device. The studied value cannot be assigned to a Thermage system or other Oligio models. The paper also describes cryogen spray cooling of the treatment tip before, during, and after each energy pulse; that detail applies to the studied device.
The cohort enrolled 30 adults. They received one treatment on day 0, with assessments on days 30, 90, and 180. The schedule describes observation, not guaranteed duration or a recommended interval.
A single-group study cannot make a device comparison
The authors reported no control group and mainly subjective evaluations. Their observations cannot directly compare the studied device with a Thermage system or show equivalence. Safety findings also come from this one cohort: 25 of 30 participants (83.3%) had immediate erythema that resolved within one to two days; one participant (3.3%) reported facial dryness at one month that resolved before the three-month visit. No serious adverse events were reported during the six-month follow-up. This does not establish risk for other devices or for one person.
Study exclusions have a study-specific scope
The cohort excluded people with an implanted electrical device, pregnancy, breastfeeding, or within three months postpartum. It also excluded those treated with RF, microfocused ultrasound, botulinum toxin, or laser in the previous six months, or with facial filler in the previous 12 months. These windows defined study entry; they are not universal contraindications or recommended waiting periods.
The full paper also lists hypertrophic scarring or keloids, active infection, herpes simplex infection, regular smoking, immunocompromise, and preexisting connective tissue disease among its exclusions. These details clarify whom the study did not include. They cannot decide whether one person is eligible.
A Korean laser-medicine society conference program lists a talk on monopolar RF principles and cooling methods. It shows what the meeting covered, without comparing cooling methods or setting a required checklist for every device discussion.
References
- Seoul National University Hospital, “주름살 [wrinkle]” (in Korean). https://www.snuh.org/health/nMedInfo/nView.do?medid=AA000739
- Wanitphakdeedecha R, et al., “Efficacy and Safety of Monopolar Radiofrequency for Treatment of Lower Facial Laxity in Asians.” Dermatology and Therapy. https://link.springer.com/article/10.1007/s13555-022-00817-8
- Korean Association for Laser Dermatology and Trichology, “대한레이저피부모발학회 제 47차 부산학술대회” (in Korean). https://kaldat.co.kr/seminar/previous/41?page=1&search_type=title
Frequently asked questions
Do Thermage and Oligio devices all operate at 6.78 MHz?
We cannot generalize that value. The cited prospective cohort used a specific Oligio device at 6.78 MHz. It gives no basis for assigning that frequency to a Thermage system or every other Oligio model.
Does follow-up through day 180 mean results last 180 days?
No. After one treatment on day 0, researchers assessed participants on days 30, 90, and 180. Those visits do not guarantee how long a result lasts or set a recommended treatment interval.
Why does the lack of a control group matter?
The authors had no control group and relied mainly on subjective evaluations. They did not compare the studied device with a Thermage system, so the study cannot show which performs better or whether their outcomes are equivalent.
Which medical and treatment history should be discussed?
The cohort screened for implanted electrical devices, pregnancy or breastfeeding, being within three months postpartum, and prior RF, microfocused ultrasound, botulinum toxin, laser, or filler treatment within specified study windows. The paper also excluded several other health conditions. These were study entry criteria, not universal contraindications or a shared waiting-period rule; individual suitability needs clinical assessment.